ARS Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held by ARS Pharmaceuticals, Inc. on June 24, 2026. The record date for the meeting was April 27, 2026, with 99,300,658 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on four proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Three Class III directors were elected to serve until the 2029 Annual Meeting.
- Saqib Islam, J.D.: 51,588,419 votes For; 14,429,366 votes Withheld.
- Phillip Schneider: 38,474,013 votes For; 27,543,772 votes Withheld.
- Laura Shawver, Ph.D.: 45,149,811 votes For; 20,867,974 votes Withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- For: 79,465,541
- Against: 102,436
- Abstain: 561,635
- Proposal 3 (Say-on-Pay): Stockholders approved, on an advisory basis, the compensation of Named Executive Officers.
- For: 57,290,450
- Against: 8,104,466
- Abstain: 622,869
- Proposal 4 (Frequency of Say-on-Pay): Stockholders selected a one-year frequency for future advisory votes on executive compensation.
- 1 Year: 52,117,264
- 2 Years: 68,816
- 3 Years: 13,442,422
Guidance, Outlook, and Management Commentary
Based on the advisory vote results, the Company determined it will hold future advisory votes on executive compensation on an annual basis until the next required frequency vote, which will be held no later than the 2032 annual meeting. The filing contains no financial guidance, risk factors, or contingencies.
Investor Verification Checklist
- Verify the specific terms of employment and compensation for the newly elected directors and Named Executive Officers referenced in the Proxy Statement filed on April 29, 2026.
- Confirm the total number of shares outstanding and voting rights as of the record date (April 27, 2026) to validate the voting percentages.
- Review the definitive Proxy Statement (Schedule 14A) for detailed disclosures regarding executive compensation and director qualifications.
- Monitor the Company's upcoming financial reports for the fiscal year ending December 31, 2026, as this 8-K contains no financial performance data.